BCPC BALCHEM CORP
Chemicals & Allied Products · Nasdaq · SEC CIK 9326 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.4%
TTM net income YoY14.5%
TTM EPS YoY16.2%
Revenue 3-yr CAGR6.2%
Net income 3-yr CAGR18.3%
Margins
Gross margin36.5%
Operating margin20.7%
Net margin15.4%
FCF margin—
EBITDA margin25.1%
Returns
ROE13.0%
ROA10.2%
ROIC (approx.)14.3%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets22.1%
Debt / equity0.00x
Current ratio2.47x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.31x
Accruals ratio-3.1%
Payout ratio18.0%
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.04B | $953.68M |
| Cost of revenue | $666.53M | $617.48M |
| Gross profit | $370.63M | $336.21M |
| R&D expense | $18.51M | $16.79M |
| SG&A expense | $67.42M | $67.59M |
| Operating income | $209.33M | $182.91M |
| Pretax income | $199.03M | $166.45M |
| Income tax | $44.19M | $37.98M |
| Net income | $154.84M | $128.47M |
| EBITDA | $255.02M | $230.88M |
| EPS (basic) | 4.80 | 3.97 |
| EPS (diluted) | 4.75 | 3.93 |
| Dividends declared per share | 0.96 | 0.87 |
| Weighted avg. shares (diluted) | 32.60M | 32.72M |
| Balance sheet | ||
| Cash & equivalents | $74.57M | $49.52M |
| Receivables | $143.60M | $119.66M |
| Inventory | $131.45M | $130.80M |
| Current assets | $365.61M | $313.77M |
| PP&E, net | $306.65M | $282.15M |
| Goodwill | $816.38M | $780.03M |
| Intangibles | $132.99M | $132.48M |
| Total assets | $1.69B | $1.58B |
| Current liabilities | $176.38M | $157.69M |
| Total liabilities | $428.84M | $425.46M |
| Shareholders' equity | $1.26B | $1.15B |
| Shares outstanding | 32.06M | 32.53M |
| Cash flow statement | ||
| Operating cash flow | $216.56M | $182.00M |
| Investing cash flow | -$43.89M | -$59.74M |
| Financing cash flow | -$152.81M | -$133.81M |
| Depreciation & amortization | $45.69M | $47.97M |
| Stock-based compensation | $18.06M | $16.68M |
| Dividends paid | $28.29M | $25.58M |
| Share buybacks | $107.64M | $5.68M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.